Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Association between patient, tumor features and response to radiotherapy, 3 months after completion

From: Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma

Features Responders non-responders Value - p
(n = 92) (n = 35)
Median Age, years (SD) 47.5 (11.9) 49.9 (12.6) 0.17
Median Tumor size, cm (SD) 6.4 (2.0) 6.7 (2.1) 0.58
FIGO staging, number of patients (%)    0.26*
   IIB 36 (78.3) 10 (21.7)  
   IIIB 56 (69.1) 25 (30.9)  
Differentiation degree, number of patients (%)
   Well 7 (77.8) 2 (22.2) 0.62*
   Moderetaly 65 (75.6) 21 (24.4)  
   Poorly 11 (64.7) 6 (35.3)  
Treatment type, number of patients (%)    0.21*
Exclusive EBRT + Brachytherapy 36 (66.7) 18 (33.3)  
Chemo-Radiotherapy + Brachytherapy 56 (76.7) 17 (23.3)  
Protein Expression, number of patients (%)
CAIX    
  Negative 63 (70) 27 (30) 0.02**₤
  Positive 19(95) 1 (5)  
HIF1 α
  Negative 27 (81.8) 6 (18.2) 0.14*₤
  Positive 63 (68.4) 29 (31.6)  
GLUT1
  Negative 52 (72.2) 20 (27.8) 0.44*₤
  Positive 30 (78.9) 8 (21.1)  
IGF1R α
  Negative 17 (65.3) 9 (34.7) 0.39*₤
  Positive 73 (73.7) 26 (26.3)  
IGF1R β
  Negative 22 (75.8) 7 (24.2) 0.59*₤
  Positive 68 (70.9) 28 (29.1)  
Survivin
  Negative 11 (78.6) 3 (21.4) 0.67*₤
  Positive 74 (73.3) 27 (26.7)  
Impact of anemia, number of patients (%)
  Hb > 11 g/dl 71 (78) 20 (21.9) 0.02*
  Hb ≤ 11 g/dl 21 (58.3) 15 (41.6)  
  1. SD: standard deviation, FIGO: International Federation of Gynecology and Obstetrics, EBRT: external beam radiotherapy
  2. *Chi2 test
  3. **Exact fisher test
  4. Type I error is set to 0.0085 in order to correct for multiple testing, based on the Dunn-Sidak’s method